U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06919666) titled 'NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma' on April 02.
Brief Summary: Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Intervention:
DRUG: NT219
NT219 is a first-in-class small molecule targeting IRS 1/2 and STAT3. Preclinical studies in melanoma have shown NT219 induces PD-L1 expression in vitro and in...